Bausch + Lomb: Update on FDA approval of XIPERE for macular edema associated with uveitis

,

Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Ophthalmology Times'® David Hutton speaks with Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, on the company's latest FDA approval of XIPERE(triamcinolone acetonide injectable suspension)for the treatment of macular edema associated with uveitis.

XIPERE is the first—and currently only— FDA-approved therapy utilizing suprachoridal administration.

See more AAO coverage